Table 3.
hr-HPV genotypes stratified by immunocompetency status based on CD4+ T cell counts at baseline among HIV-infected patients (n = 81)
| Characteristic | <350 cells/μl n = 24 | ≥350 cells/μl n = 57 | p-value1 |
|---|---|---|---|
| HPV genotypes | |||
| HPV-16 alone | 13 (54.2%) | 25 (43.9%) | N/A2 |
| HPV-16 and HPV-18 | 3 (12.5%) | 9 (15.8%) | |
| HPV-16 and other hr-HPV | 2 (8.3%) | 8 (14.0%) | |
| HPV-16, HPV-18 and other hr-HPV | 3 (12.5%) | 3 (5.3%) | |
| HPV-18 alone | 1 (4.2%) | 4 (7.0%) | |
| HPV-18 and other hr-HPV | 0 | 0 | |
| Other hr-HPV | 2 (8.3%) | 8 (14.0%) | |
| HPV genotypes (HPV-16 alone or multiple) | |||
| HPV-16 alone | 13 (54.2%) | 25 (43.9%) | 0.396 |
| Others | 11 (45.8%) | 32 (56.1%) | |
| HPV genotypes (alone or multiple) | |||
| HPV-16 or HPV-18 alone | 14 (58.3%) | 29 (50.9%) | 0.723 |
| Multiple hr-HPV genotypes | 8 (33.3%) | 20 (35.1%) | |
| HPV-16 genotype | |||
| HPV-16 present | 21 (87.5%) | 45 (79.0%) | 0.366 |
| HPV-18 genotype | |||
| HPV-18 present | 7 (29.2%) | 16 (28.1%) | 0.920 |
1
Based on Chi-squared test.
2
Statistics were not calculated due to insufficient data counts.